These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 16925506)

  • 21. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
    Hoeper MM
    Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
    [No Abstract]   [Full Text] [Related]  

  • 22. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D; Humbert M
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract]   [Full Text] [Related]  

  • 23. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
    Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
    Rondelet B; Dewachter L; Kerbaul F; Dewachter C; Hubloue I; Fesler P; Franck S; Remmelink M; Brimioulle S; Naeije R
    Am J Physiol Heart Circ Physiol; 2010 Oct; 299(4):H1118-23. PubMed ID: 20693396
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral sildenafil for persistent pulmonary hypertension early after congenital cardiac surgery in children.
    Nemoto S; Sasaki T; Ozawa H; Katsumata T; Kishi K; Okumura K; Mori Y; Umegaki O
    Eur J Cardiothorac Surg; 2010 Jul; 38(1):71-7. PubMed ID: 20206543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.
    Channick R; Preston I; Klinger JR
    Clin Chest Med; 2013 Dec; 34(4):811-24. PubMed ID: 24267306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.
    Rubin LJ; Badesch DB; Fleming TR; Galiè N; Simonneau G; Ghofrani HA; Oakes M; Layton G; Serdarevic-Pehar M; McLaughlin VV; Barst RJ;
    Chest; 2011 Nov; 140(5):1274-1283. PubMed ID: 21546436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Simvastatin and sildenafil combine to attenuate pulmonary hypertension.
    Zhao L; Sebkhi A; Ali O; Wojciak-Stothard B; Mamanova L; Yang Q; Wharton J; Wilkins MR
    Eur Respir J; 2009 Oct; 34(4):948-57. PubMed ID: 19797670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Versatile effects of sildenafil: recent pharmacological applications.
    Uthayathas S; Karuppagounder SS; Thrash BM; Parameshwaran K; Suppiramaniam V; Dhanasekaran M
    Pharmacol Rep; 2007; 59(2):150-63. PubMed ID: 17556793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling.
    Kirsch M; Kemp-Harper B; Weissmann N; Grimminger F; Schmidt HH
    FASEB J; 2008 Jan; 22(1):30-40. PubMed ID: 17679609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension.
    Archer SL; Michelakis ED
    N Engl J Med; 2009 Nov; 361(19):1864-71. PubMed ID: 19890129
    [No Abstract]   [Full Text] [Related]  

  • 33. Sildenafil citrate for the treatment of pulmonary hypertension.
    Hrometz SL; Shields KM
    Drugs Today (Barc); 2006 Dec; 42(12):771-84. PubMed ID: 17285150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular protection with sildenafil following chronic inhibition of nitric oxide synthase.
    Kukreja RC
    Br J Pharmacol; 2007 Mar; 150(5):538-40. PubMed ID: 17245364
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sustained long-term benefit of sildenafil in primary pulmonary hypertension.
    Sayin T; Ozenci M
    Acta Cardiol; 2007 Feb; 62(1):47-9. PubMed ID: 17375892
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.
    Bharani A; Mathew V; Sahu A; Lunia B
    Indian Heart J; 2003; 55(1):55-9. PubMed ID: 12760589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, tolerability, and efficacy of overnight switching from sildenafil to tadalafil in patients with pulmonary arterial hypertension.
    Shapiro S; Traiger G; Hill W; Zhang L; Doran AK
    Cardiovasc Ther; 2013 Oct; 31(5):274-9. PubMed ID: 23841794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.
    Levin YD; White RJ
    Drugs Today (Barc); 2011 Feb; 47(2):145-56. PubMed ID: 21431102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sildenafil therapy for pulmonary hypertension: a prospective study].
    Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Cheng XS; Gu Q; Zhao ZH; Zeng WJ; Zhu F; He JG
    Zhonghua Jie He He Hu Xi Za Zhi; 2011 Jun; 34(6):419-23. PubMed ID: 21781512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.